Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: PAR-25-325
Official listed status: posted
Closing information: 2027-09-10 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Applicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.
Applicant categories in federal synopsis: Public and State controlled institutions of higher education; Special district governments; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Native American tribal organizations (other than Federally recognized tribal governments); State governments; County governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); Native American tribal governments (Federally recognized); City or township governments; Private institutions of higher education; Public housing authorities/Indian housing authorities; Independent school districts
Federal synopsis
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as liquid biopsies", or other biospecimens as described in this NOFO. Extramural research funded under this NOFO may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for "liquid biopsies", tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.